Sarah Bhagat
Director/Board Member at INOZYME PHARMA, INC.
Net worth: - $ as of 31/05/2024
Network origin in Sarah Bhagat first degree
Entity | Entity type | Industry | |
---|---|---|---|
Yale University
326
| College/University | Other Consumer Services | 326 |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California.
25
| Private Company | Investment Managers | 25 |
Public Company | Pharmaceuticals: Major | 25 | |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC.
10
| Holding Company | Biotechnology | 10 |
Aeovian Pharmaceuticals, Inc.
Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Sarah Bhagat via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Human Resources Officer | |
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Investment Banks/Brokers | Analyst-Equity Analyst-Equity | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Washington University in St. Louis | College/University | Director/Board Member Undergraduate Degree | |
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
AMARIN CORPORATION PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Miscellaneous Commercial Services | Founder Director/Board Member | |
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
HYPERION THERAPEUTICS INC | Pharmaceuticals: Major | Chairman Director/Board Member | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Founder Chairman Director/Board Member | |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Investment Banks/Brokers | Market Strategist Corporate Officer/Principal | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Masters Business Admin Doctorate Degree Undergraduate Degree | |
Stanford University | College/University | Undergraduate Degree Undergraduate Degree Masters Business Admin Undergraduate Degree Masters Business Admin Undergraduate Degree Doctorate Degree Masters Business Admin Masters Business Admin | |
University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree Undergraduate Degree Undergraduate Degree | |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Analyst-Equity Market Strategist Analyst-Fixed Income | |
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Investment Banks/Brokers | Analyst-Equity Corporate Officer/Principal Analyst-Equity | |
McGill University | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
The Johns Hopkins University | College/University | Doctorate Degree Graduate Degree | |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
University of California, Berkeley | College/University | Undergraduate Degree Corporate Officer/Principal | |
ENANTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Sofinnova Management VI LLC | Corporate Officer/Principal Corporate Officer/Principal | ||
Morgenthaler Management Corp.
Morgenthaler Management Corp. Investment ManagersFinance Morgenthaler Management Corp (Morgenthaler Management) is a venture capital and private equity firm founded in 1968 by David Morgenthaler. The firm is headquartered in Portola Valley, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Longitude Capital Management Co LLC
Longitude Capital Management Co LLC Investment ManagersFinance Longitude Capital Management Co LLC (Longitude Capital) is a venture capital firm founded in 2006 by Juliet Trammenoms Bakker, Patrick Enright, David Hirsch and Marc-Henri Galletti. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Quanta Therapeutics, Inc.
Quanta Therapeutics, Inc. BiotechnologyHealth Technology Quanta Therapeutics, Inc. develops biotechnologies. The American company was founded in 2018 by Cameron Pitt, Frank McCormick. Perry D. Nisen has been the CEO of the company since 2021. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AKOUOS | Biotechnology | Director/Board Member Chief Operating Officer | |
LSV CAPITAL MANAGEMENT LLC
LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Investment Managers | Consultant / Advisor Private Equity Investor | |
ITERUM THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
CRISPR THERAPEUTICS AG | Biotechnology | Director/Board Member Corporate Officer/Principal | |
OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Pionyr Immunotherapeutics, Inc.
Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Yale Law School | College/University | Graduate Degree Graduate Degree | |
DURATA THERAPEUTICS INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
VENTYX BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Sectoral Asset Management Inc (Private Equity)
Sectoral Asset Management Inc (Private Equity) Investment ManagersFinance Sectoral Asset Management Inc (Private Equity) (Sectoral Asset Management) is a private equity subsidiary of Sectoral Asset Management, Inc. founded in 2008 by Michael Sjöström. The firm is headquartered in Montréal, Quebec. | Investment Managers | Private Equity Investor Private Equity Analyst | |
SOLID BIOSCIENCES INC. | Biotechnology | Director of Finance/CFO Director/Board Member | |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Pharmaceuticals: Generic | Chief Executive Officer Founder | |
The University of Texas Southwestern Medical Center | College/University | Corporate Officer/Principal Graduate Degree |
Statistics
International
United States | 41 |
Ireland | 4 |
Switzerland | 4 |
Canada | 3 |
United Kingdom | 2 |
Sectoral
Health Technology | 25 |
Consumer Services | 14 |
Finance | 9 |
Commercial Services | 5 |
Operational
Director/Board Member | 337 |
Corporate Officer/Principal | 154 |
Independent Dir/Board Member | 86 |
Undergraduate Degree | 85 |
Private Equity Investor | 80 |
Most connected contacts
Insiders | |
---|---|
James Healy | 50 |
Michael Powell | 48 |
Ed Mathers Mathers | 47 |
William Kennard | 39 |
Martin Edwards | 38 |
Maha Katabi | 28 |
Jens Eckstein | 27 |
Stephen DiPalma | 24 |
Axel Bolte | 23 |
Jason Lettmann | 21 |
Robert Hopfner | 20 |
Adrian Horotan | 18 |
Richard Gaster | 17 |
Reinaldo Diaz | 17 |
Sunil Agarwal | 17 |
- Stock Market
- Insiders
- Sarah Bhagat
- Company connections